Tanvex BioPharma, Inc.

Equities

6541

KYG8676P1037

Biotechnology & Medical Research

End-of-day quote Taiwan S.E. Other stock markets 06:00:00 2024-07-11 pm EDT			5-day change	1st Jan Change
68.8 ^TWD	-2.41%		+1.78%	+5.68%

Jun. 28	Tanvex BioPharma, Inc. Announces CFO Changes, Effective June 30, 2024	CI
Jun. 19	Tanvex BioPharma, Inc. Appoints Val Chen as Corporate Governance Officer, Effective July 1, 2024	CI

Tanvex BioPharma, Inc. Announces CFO Changes, Effective June 30, 2024

June 28, 2024 at 07:20 am EDT

Tanvex BioPharma, Inc. announced that name, title, and resume of the previous position holder: Kevin Yeh, CFO. Name, title, and resume of the new position holder: Val Chen/VP of Finance of Tanvex BioPharma Inc. Effective date is June 30, 2024.

Latest news about Tanvex BioPharma, Inc.

Tanvex BioPharma, Inc. Announces CFO Changes, Effective June 30, 2024	Jun. 28	CI
Tanvex BioPharma, Inc. Appoints Val Chen as Corporate Governance Officer, Effective July 1, 2024	Jun. 19	CI
Tanvex BioPharma, Inc. Announces Change of Audit Committee Members	Jun. 19	CI
Tanvex BioPharma, Inc. Announces Change of Remuneration Committee Members	Jun. 19	CI
Tanvex BioPharma, Inc. Announces Board Changes	Jun. 19	CI
Tanvex BioPharma, Inc.(TWSE:6541) dropped from Taiwan TAIEX Index	Jun. 13	CI
Tanvex BioPharma, Inc.(TWSE:6541) dropped from S&P Global BMI Index	May. 27	CI
Tanvex BioPharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 12	CI
Tanvex BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
Tanvex BioPharma, Inc. Announces the Appointment of James Williamson as Accounting Officer	Feb. 06	CI
Tanvex BioPharma, Inc. Announces the Appointment of Chen, Lin-Cheng as CEO	Feb. 06	CI
Tanvex Biologics Corporation announced that it expects to receive $5 million in funding from Tanvex BioPharma, Inc.	Feb. 05	CI
Tanvex BioPharma USA, Inc. announced that it expects to receive $50 million in funding from Tanvex BioPharma, Inc.	Feb. 05	CI
Tanvex BioPharma, Inc. Announces the Resignation of Ken Huang as Accounting Officer	Jan. 05	CI
Tanvex BioPharma, Inc. Announces Change of Chairman	Dec. 29	CI
Tanvex BioPharma, Inc. Announces Resignation of Yun Yen Chairperson and Director, Effective December 29, 2023	Dec. 21	CI
Tanvex BioPharma, Inc. Announces Change of Corporate Governance Officer	Dec. 21	CI
Tanvex BioPharma, Inc. Announces Resignation of Yun Yen as CEO, Effective December 29, 2023	Dec. 21	CI
Tanvex BioPharma, Inc. Announces Resignation of Yun Yen as Chairman/President, Effective December 29, 2023	Dec. 21	CI
Tanvex BioPharma, Inc. Announces the Resignation of Stacey Tsai as Acting Spokesperson and Corporate Governance Officer	Nov. 30	CI
Tanvex BioPharma, Inc. Appoints Wen Chung Yeh as Chief Financial Officer	Nov. 13	CI
Tanvex BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 12	CI
Tanvex BioPharma, Inc. Announces Management Changes	Nov. 01	CI
Tanvex BioPharma, Inc.(TWSE:6541) added to S&P Global BMI Index	23-09-17	CI
Tanvex BioPharma, Inc.(TWSE:6541) added to Taiwan TAIEX Index	23-09-06	CI

Chart Tanvex BioPharma, Inc.

Duration

Period

More charts

Company Profile

Tanvex BioPharma, Inc. is a Cayman Islands-based biopharmaceutical company focused on the biosimilar market. The company has expertise in areas, including strain and cell-line development in both microbial and mammalian systems, cell culture, protein purification, process scale-up, drug substance and product manufacturing, and others. The Companyâs product pipeline includes Neupogen (TX-01), Herceptin (TX-05), Neulasta (TX-04), Avastin (TX-16), Perjeta (TX-52), and others. The Company offers a vertically integrated manufacturing platform for biopharmaceuticals. The Company is developing and delivering biologic and biosimilar drugs to people.

Sector

Biotechnology & Medical Research

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
TANVEX BIOPHARMA, INC.	+5.68%	347M
VERTEX PHARMACEUTICALS INCORPORATED	+20.12%	126B
REGENERON PHARMACEUTICALS, INC.	+25.25%	119B
ARGENX SE	+25.56%	27.95B
BIONTECH SE	-19.51%	20.5B
GENMAB A/S	-14.36%	17.12B
BEIGENE, LTD.	-15.63%	16.1B
WUXI APPTEC CO., LTD.	-46.67%	14.97B
NEUROCRINE BIOSCIENCES, INC.	+11.89%	14.84B
SAREPTA THERAPEUTICS, INC.	+57.74%	14.38B

Bio Therapeutic Drugs